Opportunity Information: Apply for RFA AI 16 003
Apply for RFA AI 16 003
- The HHS-NIH11 in the health sector is offering a public funding opportunity titled "Cooperative Study Group for Autoimmune Disease Prevention (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855, 93.856,.
- This funding opportunity was created on Feb 25, 2016 and posted on Feb 25, 2016.
- Applicants must submit their applications by Jun 29, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $1,600,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Cooperative Study Group for Autoimmune Disease Prevention (U01) grant opportunity (Funding Opportunity Number RFA AI 16 003) is a National Institutes of Health (NIH) funding announcement under the U.S. Department of Health and Human Services, listed as HHS-NIH11. It uses a cooperative agreement mechanism (U01), which generally means the funded projects are expected to operate as part of a coordinated program with substantial scientific and programmatic involvement from NIH staff, rather than functioning as fully independent investigator-initiated awards. The overall purpose is to build and sustain a cooperative study group that can generate the scientific evidence needed to prevent human autoimmune diseases.
The core scientific focus is prevention, with an emphasis on developing a reliable knowledge base that can support the design of selective preventive interventions. In practical terms, the FOA is aimed at studies that help identify who is at risk, when prevention should occur, what biological pathways or environmental factors might be targeted, and how an intervention could be delivered safely and efficiently. A notable element of the announcement is its explicit interest in prevention strategies that could ultimately be used either broadly in the general population or in defined at-risk groups, including infants and children. That framing signals interest in early-life windows of immune development and in approaches that balance public health scalability with strong safety expectations, since prevention implies intervening before disease onset.
Eligibility is broad and includes many types of organizations that could reasonably contribute to large, multi-site clinical and translational research efforts. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations both with and without 501(c)(3) status (excluding higher education institutions in those categories); for-profit organizations other than small businesses; small businesses; and additional eligible entities as described in the FOA’s eligibility clarification text. This wide eligibility range supports the cooperative study group model, where multiple institutions and sectors may need to collaborate to recruit participants, conduct longitudinal follow-up, perform laboratory analyses, and coordinate data management and statistical work.
From an administrative and funding standpoint, the opportunity is categorized as discretionary funding and falls under the Health activity category, with CFDA numbers 93.855 and 93.856. The posting and creation dates were February 25, 2016, and the application due date (both original and current closing date) was June 29, 2016. The listed award ceiling is $1,600,000. While the posting includes an “ExpectedAwards” field, the number of anticipated awards is not provided in the supplied source data, so applicants would have needed to consult the full FOA for award count expectations and program structure details.
In summary, this FOA supported the formation or participation of institutions and consortia in a coordinated NIH-led research effort to move autoimmune disease prevention forward, particularly by generating the evidence needed to design preventive interventions that are selective, safe, and feasible to deploy at scale, including for pediatric and early-life populations.
Frequently Asked Questions (FAQs): Cooperative Study Group for Autoimmune Disease Prevention (U01)
What is the name of this grant opportunity?
The opportunity is titled the Cooperative Study Group for Autoimmune Disease Prevention (U01).
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is RFA AI 16 003.
Which agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding announcement under the U.S. Department of Health and Human Services.
How is the opportunity listed at the department level?
It is listed as HHS-NIH11.
What type of funding mechanism is being used?
The mechanism is a cooperative agreement (U01).
What does a cooperative agreement (U01) generally imply for how the project will operate?
A U01 generally indicates that the funded projects are expected to operate as part of a coordinated program with substantial scientific and programmatic involvement from NIH staff, rather than functioning as fully independent investigator-initiated awards.
What is the overall purpose of this FOA?
The overall purpose is to build and sustain a cooperative study group that can generate the scientific evidence needed to prevent human autoimmune diseases.
What is the central scientific focus of the announcement?
The core scientific focus is prevention of human autoimmune diseases.
What kinds of research questions is this FOA trying to support?
It is aimed at studies that help establish a reliable knowledge base for designing selective preventive interventions, including questions such as: who is at risk, when prevention should occur, what biological pathways or environmental factors could be targeted, and how an intervention could be delivered safely and efficiently.
Is the FOA focused on broad public health prevention or only on high-risk individuals?
The announcement explicitly expresses interest in prevention strategies that could ultimately be used either broadly in the general population or in defined at-risk groups.
Does the FOA include pediatric or early-life prevention as an area of interest?
Yes. It includes defined at-risk groups that may include infants and children, signaling interest in early-life windows of immune development.
Why does the FOA emphasize safety and feasibility for preventive interventions?
Because prevention implies intervening before disease onset, the FOA frames interest in approaches that balance public health scalability with strong safety expectations and practical, efficient delivery.
What kinds of organizations are eligible to apply?
Eligibility is broad. Eligible applicants include government entities and a wide range of academic, nonprofit, and commercial organizations, as described in the FOA and eligibility clarification text.
Are state and local governments eligible?
Yes. Eligible applicants include state governments, county governments, city/township governments, and special district governments.
Are independent school districts eligible?
Yes. Independent school districts are listed among eligible applicants.
Are colleges and universities eligible?
Yes. Both public/state-controlled institutions of higher education and private institutions of higher education are eligible.
Are federally recognized Native American tribal governments eligible?
Yes. Federally recognized Native American tribal governments are eligible.
Are other Native American tribal organizations eligible?
Yes. Other Native American tribal organizations (other than federally recognized tribal governments) are listed as eligible.
Are public housing authorities eligible?
Yes. Public housing authorities and Indian housing authorities are listed as eligible.
Are nonprofit organizations eligible?
Yes. Nonprofit organizations with 501(c)(3) status and nonprofits without 501(c)(3) status are listed as eligible (excluding higher education institutions in those nonprofit categories).
Are for-profit entities eligible?
Yes. For-profit organizations other than small businesses are eligible, and small businesses are also eligible.
Does the FOA allow additional eligible entities beyond the list shown?
Yes. The eligibility list includes "additional eligible entities as described in the FOA's eligibility clarification text."
Why might the eligibility be so broad for this opportunity?
The description ties the broad eligibility range to the cooperative study group model, where multiple institutions and sectors may need to collaborate to recruit participants, conduct longitudinal follow-up, perform laboratory analyses, and coordinate data management and statistical work.
What activity category does this funding fall under?
The opportunity falls under the Health activity category.
Is this considered discretionary funding?
Yes. The opportunity is categorized as discretionary funding.
What CFDA numbers are associated with this opportunity?
The CFDA numbers listed are 93.855 and 93.856.
When was the opportunity posted?
The posting date is February 25, 2016.
When was the opportunity created?
The creation date is February 25, 2016.
What was the application due date?
The application due date was June 29, 2016 (both the original and current closing date are listed as June 29, 2016).
What is the maximum award amount listed (award ceiling)?
The listed award ceiling is $1,600,000.
How many awards were expected to be made?
An "ExpectedAwards" field is referenced, but the number of anticipated awards is not provided in the supplied source data. The full FOA would have been the place to confirm award count expectations and program structure details.
In plain terms, what kind of effort was this FOA supporting?
It supported the formation or participation of institutions and consortia in a coordinated NIH-led research effort focused on moving autoimmune disease prevention forward by generating evidence needed to design preventive interventions that are selective, safe, and feasible to deploy at scale, including for pediatric and early-life populations.
Browse more opportunities from the same category: Health
Next opportunity: Stimulating Peripheral Activity to Relieve Conditions (SPARC): Pre-clinical Development of Existing Market-approved Devices to Support New Market Indications (U18)
Previous opportunity: Clean Diesel Funding Assistance Program FY 2016
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 16 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 16 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Stimulating Peripheral Activity to Relieve Conditions (SPARC): Pre-clinical Development of Existing Market-approved Devices to Support New Market Indications (U18) Apply for RFA RM 16 009 Funding Number: RFA RM 16 009 Agency: HHS-NIH11 Category: Health Funding Amount: $400,000 |
| Public Health Surveillance for the Prevention of Complications of Bleeding Disorders Apply for CDC RFA DD15 150702CONT16 Funding Number: CDC RFA DD15 150702CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement with the Chinese Center for Disease Control and Prevention Apply for CDC RFA GH12 124705CONT16 Funding Number: CDC RFA GH12 124705CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Optimization of Monoclonal Antibodies for Eliminating the HIV Reservoir (R01) Apply for PAR 16 115 Funding Number: PAR 16 115 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Addiction Technology Transfer Center: Networking Coordinating Office for Internationally-based Addiction Technology Transfer Centers (Short Title: Global-ATTC) Apply for TI 16 015 Funding Number: TI 16 015 Agency: HHS-SAMHS Category: Health Funding Amount: $100,000 |
| Small Vessel Vascular Contributions to Cognitive Impairment and Dementia (VCID) Biomarkers Consortium: Coordinating Center (U24) Apply for RFA NS 16 019 Funding Number: RFA NS 16 019 Agency: HHS-NIH11 Category: Health Funding Amount: $750,000 |
| Enhancing Cancer Genomic Best Practices through Education, Surveillance, and Policy Apply for CDC RFA DP14 140703CONT16 Funding Number: CDC RFA DP14 140703CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Defeat Malaria Apply for RFA 482 16 000001 Funding Number: RFA 482 16 000001 Agency: USAID-BMA Category: Health Funding Amount: $32,000,000 |
| Improving Response to and Programming in Humanitarian Emergencies Apply for CDC RFA GH15 162302CONT16 Funding Number: CDC RFA GH15 162302CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Pragmatic Strategies for Assessing Psychotherapy Quality in Practice (R01) Apply for RFA MH 17 500 Funding Number: RFA MH 17 500 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Small Vessel Vascular Contributions to Cognitive Impairment and Dementia (VCID) Biomarkers Development Projects (UH2/UH3) Apply for RFA NS 16 020 Funding Number: RFA NS 16 020 Agency: HHS-NIH11 Category: Health Funding Amount: $750,000 |
| Partner Support for Heart Disease and Stroke Prevention Apply for CDC RFA DP15 150402CONT16 Funding Number: CDC RFA DP15 150402CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| National Public Health Practice and Resource Centers for Children with Attention Deficit/Hyperactivity Disorder or Tourette Syndrome Apply for CDC RFA DD15 150502CONT16 Funding Number: CDC RFA DD15 150502CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Strategic Approaches to Improving Access to Quality Health Care for Children and Youth with Epilepsy Apply for HRSA 16 055 Funding Number: HRSA 16 055 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Developing professional training programs to increase capacity for effective global health response to humanitarian emergencies Apply for CDC RFA GH15 162402CONT16 Funding Number: CDC RFA GH15 162402CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Programs to Reduce Obesity in High Obesity Areas Apply for CDC RFA DP14 141603CONT16 Funding Number: CDC RFA DP14 141603CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| PPHF 2016: Office of Smoking and Health – Public Health Approaches for Ensuring Quitline Capacity – Financed solely by 2016 Prevention and Public Health Funds Apply for CDC RFA DP14 141003CONTPPHF16 Funding Number: CDC RFA DP14 141003CONTPPHF16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Targeted Capacity Expansion HIV: Substance Use Disorder Treatment for Racial/Ethnic Minority Women at High Risk for HIV/AIDS (Short Title: TCE-HIV: Minority Women) Apply for TI 16 011 Funding Number: TI 16 011 Agency: HHS-SAMHS-SAMHSA Category: Health Funding Amount: $500,000 |
| PPHF 2016: National Early Child Care Collaboratives - Early Care and Education Statewide Collaboratives to Improve Nutrition, Breastfeeding Support, Physical Activity and Screen Time Practices for Obesity Prevention in Young Children Apply for CDC RFA DP12 121505CONTPPHF16 Funding Number: CDC RFA DP12 121505CONTPPHF16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Early Childhood Comprehensive Systems Collaborative Improvement and Innovation Network Coordination Center (ECCS CoIIN CC) Apply for HRSA 16 179 Funding Number: HRSA 16 179 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 16 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.